• Learning if the study drug is effective in reducing symptoms of HS
• Learning if it is safe for HS patients to take the study drug
• Determining whether using the study drug helps patients more than using no active treatment (placebo)

In this HS study, there are two treatment periods. You may receive the study treatment drug or a placebo during the first treatment period. A placebo contains no active treatment and is often referred to as a “sugar pill” or “dummy treatment”. A placebo is used to make sure that the changes that you report are not happening by chance.

During the first treatment period, 2 out of 3 participants (66%) will receive the investigational study drug, while 1 out of 3 (33%) will receive a placebo. Participants will not know in which group they have been placed.

During the second treatment period, all participants (100%) will receive the study drug. All participants are helping medical scientists gain additional knowledge of HS treatment and helping others who suffer from this disease.

The goal of treatment is to lower the activity of parts of the immune system that are overactive and cause inflammation and disease in patients with HS. This may reduce HS signs and symptoms. This study treatment is investigational and has not yet been approved by the United States Food and Drug Administration (FDA) for the treatment of patients with HS and is not currently available for you to buy in any country.

All clinical research studies are monitored closely to ensure patient safety.

While enrolled in the study, participants will be under the care of a research team including study doctors, study nurses, and other research staff. Patients who are considering participation should consult with their doctors before enrolling in a research study.